Crossmark

Integrated proteomics and metabolomics analyses reveal new insights into the antitumor effects of valproic acid plus simvastatin combination in a prostate cancer xenograft model associated with downmodulation of YAP/TAZ signaling

Crossref DOI link: https://doi.org/10.1186/s12935-024-03573-1

Published Online: 2024-11-16

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Iannelli, Federica

Lombardi, Rita

Costantini, Susan

Roca, Maria Serena

Addi, Laura

Bruzzese, Francesca

Di Gennaro, Elena

Budillon, Alfredo

Pucci, Biagio
Funding

Funding for this research was provided by:

Ministero della Salute (Ricerca Corrente Funds - Linea 2/2 to AB)

Regione Campania (POR FESR 2014/2020 Progetto Campania Onco-Terapie/CUP: B61G18000470007)
License Information

Text and Data Mining valid from 2024-11-16

Version of Record valid from 2024-11-16
More Information

Article History

Received: 12 March 2024

Accepted: 11 November 2024

First Online: 16 November 2024

Declarations

:

: Not applicable.

: The authors declare no competing interests.

Document is current

Any future updates will be listed below